Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Hyloris Developments SA has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units. This distribution shows that each pending matter is being handled in a different art unit by a different examiner. Such a spread suggests that the company's pending applications cover different technical niches within the broader Biotechnology & Pharmaceuticals sector.
COHEN, MICHAEL P is the busiest examiner for the company, handling 1 pending office action. With 2 distinct examiners for 2 pending actions, the workload is evenly divided across the assigned personnel. For the practitioner, this means that separate prosecution strategies are required, as there is no overlap in examiners or art units. The use of 2 distinct art units for only 2 actions indicates that the company's current pending matters are technically diverse, requiring engagement with different administrative groups at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 1 | 59.0% | +27.3% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18775374 | LYOPHILIZED METOLAZONE FORMULATION FOR PARENTERAL ADMINISTRATION | COHEN, MICHAEL P | — |
| 18328975 | TRANEXAMIC ACID ORAL SOLUTION | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18775374 | LYOPHILIZED METOLAZONE FORMULATION FOR PARENTERAL ADMINISTRATION | COHEN, MICHAEL P | 1612 | §103 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18328975 | TRANEXAMIC ACID ORAL SOLUTION | LEE, ANDREW P | 1691 | Other | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHyloris Developments SA has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Michael P Cohen has the most, with 1 of Hyloris Developments SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.